ECSP11011240A - Conjugados de insulina cristalina - Google Patents
Conjugados de insulina cristalinaInfo
- Publication number
- ECSP11011240A ECSP11011240A EC2011011240A ECSP11011240A ECSP11011240A EC SP11011240 A ECSP11011240 A EC SP11011240A EC 2011011240 A EC2011011240 A EC 2011011240A EC SP11011240 A ECSP11011240 A EC SP11011240A EC SP11011240 A ECSP11011240 A EC SP11011240A
- Authority
- EC
- Ecuador
- Prior art keywords
- insulin
- crystalline
- formulations
- conjugates
- protamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En un aspecto, la divulgación proporciona métodos para controlar los perfiles farmacocinéticos (PK) y/o farmacodinámicos (PD) de insulina de una forma que es sensible a las concentraciones sistémicas de un sacárido tal como la glucosa. Como se discute en los Ejemplos, se descubrió que cuando la insulina fuera conjugada con ligandos sacáridos de alta afinidad, pudo hacerse para exhibir perfiles PK/PD que respondieran a cambios de concentración sacárida aún en ausencia de una molécula multivalente y exógena fijadora de sacáridos tal como Con A. Este hallazgo fue inesperado y proporciona una oportunidad sin precedentes para generar sistemas simples de insulina sensibles a sacáridos libres de lectina.Las formulaciones de liberación sostenida de insulinas convencionales comúnmente se utilizan para retardar la liberación de insulina en circulación sistémica. Por ejemplo, las formulaciones PZI (insulina de protamina de zinc) pueden utilizarse para este propósito. Cuando se formulan insulinas convencionales con protamina y zinc, generalmente se producen formulaciones de liberación sostenida cristalinas. Por el contrario, cuando se formulan los conjugados de insulina descritos en la presente con protamina y zinc utilizando métodos similares, se producen formulaciones amorfas, y se requiere mucha más protamina y zinc para proporcionar liberación sostenida que la requerida para insulinas convencionales, ej. RHI (insulina humana recombinante). Sorprendentemente se ha descubierto que ciertos conjugados de insulina descritos en la presente pueden cristalizarse. Los conjugados de insulina son difíciles de cristalizar utilizando condiciones estándares de cristalización de insulina, más probablemente debido a sus estructuras estéricamente voluminosas que contienen sacáridos. Como se describió en la presente, los conjugados de insulina cristalina de la presente divulgación pueden entonces formularse para proporcionar formulaciones de liberación sostenida cristalinas. La presente divulgación proporciona conjugados de insulina cristalina y formulaciones de los mismos. También se proporcionan métodos para fabricar y utilizar conjugados de insulina cristalina. Las formulaciones cristalinas de los conjugados de insulina pueden ser ventajosas para mejorar reproducibilidad de lote en lote, aumentando estabilidad de la formulación, y disminuyendo la aglomeración de partículas durante largos periodos de almacenamiento.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14787809P | 2009-01-28 | 2009-01-28 | |
| US15964309P | 2009-03-12 | 2009-03-12 | |
| US16210709P | 2009-03-20 | 2009-03-20 | |
| US16308409P | 2009-03-25 | 2009-03-25 | |
| US21989709P | 2009-06-24 | 2009-06-24 | |
| US22357209P | 2009-07-07 | 2009-07-07 | |
| US25285709P | 2009-10-19 | 2009-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011240A true ECSP11011240A (es) | 2011-11-30 |
Family
ID=42395986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011240A ECSP11011240A (es) | 2009-01-28 | 2011-07-28 | Conjugados de insulina cristalina |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US9050370B2 (es) |
| EP (1) | EP2391218B1 (es) |
| JP (3) | JP5508438B2 (es) |
| KR (2) | KR20110104081A (es) |
| CN (2) | CN102365025A (es) |
| AU (2) | AU2015202871B2 (es) |
| BR (1) | BRPI1007457A2 (es) |
| CA (2) | CA2932926C (es) |
| CO (1) | CO6400173A2 (es) |
| CR (1) | CR20110408A (es) |
| DO (1) | DOP2011000244A (es) |
| EA (1) | EA027757B1 (es) |
| EC (1) | ECSP11011240A (es) |
| ES (1) | ES2791683T3 (es) |
| GT (1) | GT201100208A (es) |
| IL (1) | IL214099A0 (es) |
| MA (1) | MA33064B1 (es) |
| MX (1) | MX2011007929A (es) |
| NI (1) | NI201100150A (es) |
| NZ (1) | NZ594248A (es) |
| PE (1) | PE20120583A1 (es) |
| SG (3) | SG173112A1 (es) |
| TN (1) | TN2011000354A1 (es) |
| WO (1) | WO2010088294A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012516339A (ja) | 2009-01-28 | 2012-07-19 | スマートセルズ・インコーポレイテツド | 外因的刺激型制御放出物質体およびその使用 |
| WO2010088286A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
| WO2010088294A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Conjugate based systems for controlled drug delivery |
| JP2012520879A (ja) | 2009-03-20 | 2012-09-10 | スマートセルズ・インコーポレイテツド | 末端官能基化コンジュゲートおよびその用途 |
| US9095623B2 (en) | 2009-03-20 | 2015-08-04 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
| WO2012015681A2 (en) * | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| AU2011282983A1 (en) * | 2010-07-28 | 2013-02-21 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| JP2013535467A (ja) | 2010-07-28 | 2013-09-12 | スマートセルズ・インコーポレイテツド | 組換えにより発現されたインスリンポリペプチドおよびその使用 |
| WO2012015691A2 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinant lectins, binding-site modified lectins and uses thereof |
| WO2012050822A1 (en) * | 2010-10-14 | 2012-04-19 | Smartcells, Inc. | Uses of macrophage mannose receptor to screen compounds and uses of these compounds |
| AR087433A1 (es) * | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
| TWI439288B (zh) * | 2012-10-05 | 2014-06-01 | Univ China Medical | 藥用載體及其製備方法與用途 |
| US9828341B2 (en) * | 2012-11-28 | 2017-11-28 | Victoria Link Limited | Dendritic core compounds |
| EP2925345B1 (en) | 2012-12-03 | 2018-09-05 | Merck Sharp & Dohme Corp. | Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues |
| EP2948166B1 (en) * | 2013-01-22 | 2020-12-09 | Case Western Reserve University | N-terminal truncated insulin analogues |
| US9884125B2 (en) | 2013-10-04 | 2018-02-06 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
| EP3280450A4 (en) * | 2015-04-08 | 2018-12-12 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
| MX2018014929A (es) * | 2016-06-02 | 2019-08-26 | Sanofi Sa | Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa. |
| DK3570874T3 (da) * | 2017-01-17 | 2023-04-11 | Univ Wayne State | Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder |
| US11186603B2 (en) | 2017-03-23 | 2021-11-30 | Victoria Link Limited | Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses |
| US11041009B2 (en) | 2017-03-23 | 2021-06-22 | Merck Sharp & Dohme Corp. | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes |
| CN111433193A (zh) | 2017-12-01 | 2020-07-17 | 赛诺菲 | 药剂和能够结合至葡萄糖传感蛋白的部分的新型缀合物 |
| US11820805B2 (en) * | 2017-12-18 | 2023-11-21 | Merck Sharp & Dohme Llc | Conjugate based systems for controlled insulin delivery |
| CN108610494B (zh) * | 2018-03-20 | 2020-11-06 | 南京理工大学 | 聚醚砜/功能性含糖聚合物杂化膜的制备方法 |
| CN110146605A (zh) * | 2019-04-19 | 2019-08-20 | 南通联亚药业有限公司 | 一种测定格列吡嗪原料药及其缓释片中特定基因毒性杂质的分析方法 |
| US12427187B2 (en) | 2019-06-06 | 2025-09-30 | Merck Sharp & Dohme Llc | Glucose-responsive insulin conjugates |
| CN113773400B (zh) * | 2020-06-09 | 2023-08-18 | 宁波鲲鹏生物科技有限公司 | 一种门冬胰岛素衍生物及其应用 |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| CN112480184A (zh) * | 2020-12-09 | 2021-03-12 | 上海应用技术大学 | 一种利用梯度点击化学合成含多种糖的树枝化糖胺的方法 |
| CN117321695A (zh) | 2021-05-05 | 2023-12-29 | 诺和诺德股份有限公司 | 葡萄糖敏感性胰岛素的活性胰岛素 |
| AU2023373632A1 (en) * | 2022-11-01 | 2025-05-01 | Samyang Holdings Corporation | Lipid having amide and ester functional groups, and method for producing same |
| AU2023382803A1 (en) * | 2022-11-16 | 2025-05-22 | Samyang Holdings Corporation | Nanoparticle composition for drug delivery |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US39055A (en) | 1863-06-30 | Improvement in churns | ||
| US3591574A (en) | 1968-05-29 | 1971-07-06 | American Home Prod | Tri-n-phenylglycyl derivatives of insulin |
| DE1793517C3 (de) | 1968-09-28 | 1974-12-05 | Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt | N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung |
| US3697502A (en) | 1969-11-03 | 1972-10-10 | Christensen Henry M | Method of making iron dextran-preparations |
| US3847890A (en) | 1971-11-01 | 1974-11-12 | A Green | Acidic monosaccharide-substituted proteins |
| US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
| US4377567A (en) | 1978-10-02 | 1983-03-22 | The Procter & Gamble Company | Lipid membrane drug delivery |
| EP0009842B1 (en) | 1978-10-02 | 1982-11-10 | THE PROCTER & GAMBLE COMPANY | Liposomes for drug delivery and composition containing a liposome drug system |
| US4348387A (en) * | 1979-07-31 | 1982-09-07 | The Rockefeller University | Method and system for the controlled release of biologically active substances to a body fluid |
| US4421685A (en) | 1980-03-27 | 1983-12-20 | Eli Lilly And Company | Process for producing an insulin |
| JPS608000B2 (ja) | 1980-04-11 | 1985-02-28 | 呉羽化学工業株式会社 | アミノフエニル誘導体及び該誘導体を含有する生理活性剤 |
| US4435173A (en) | 1982-03-05 | 1984-03-06 | Delta Medical Industries | Variable rate syringe pump for insulin delivery |
| US4498843A (en) | 1982-08-02 | 1985-02-12 | Schneider Philip H | Insulin infusion pump |
| US4444683A (en) | 1982-11-17 | 1984-04-24 | University Of Utah | Glycosylated insulin derivatives |
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| EP0119650A3 (en) | 1983-03-21 | 1987-09-30 | THE PROCTER & GAMBLE COMPANY | Galactosyl-insulin conjugates useful in treating diabetics |
| US4863896A (en) | 1984-05-03 | 1989-09-05 | Technology Unlimited, Inc. | Diabetic control by combined insulin forms |
| DK160633C (da) | 1985-05-15 | 1991-09-02 | Henning Munk Ejlersen | Slangepumpe, isaer til avendelse som insulinpumpe |
| US5395924A (en) | 1986-03-20 | 1995-03-07 | Dana-Farber Cancer Institute, Inc. | Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity |
| US5239062A (en) | 1986-03-20 | 1993-08-24 | Dana-Farber Cancer Institute, Inc. | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity |
| US5527524A (en) * | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
| US4853218A (en) * | 1987-02-24 | 1989-08-01 | Schering Corporation | Zinc-protamine-alpha interferon complex |
| US5062841A (en) | 1988-08-12 | 1991-11-05 | The Regents Of The University Of California | Implantable, self-regulating mechanochemical insulin pump |
| DK111489D0 (da) | 1989-03-08 | 1989-03-08 | Novo Nordisk As | Peptider |
| CA2027930C (en) | 1989-10-19 | 1998-06-30 | Tsuyoshi Miyazaki | Polymer complexes of a sugar response type |
| IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| RU2003351C1 (ru) * | 1991-06-26 | 1993-11-30 | Липов Борис Петрович; Сафронов Игорь Николаевич | Инъектор |
| GB9200638D0 (en) | 1992-01-10 | 1992-03-11 | Leicester Polytechnic | Drug system |
| JP3455217B2 (ja) | 1992-02-13 | 2003-10-14 | バイオ−メトリック システムズ インコーポレイテッド | 架橋マトリックス中の化学種の固定 |
| GB9316895D0 (en) | 1993-08-13 | 1993-09-29 | Guy S And St Thomas Hospitals | Hepatoselective insulin analogues |
| GB9313484D0 (en) | 1993-06-30 | 1993-08-11 | Univ Montfort | Drug system ii |
| US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
| NZ273285A (en) * | 1993-09-17 | 1997-10-24 | Novo Nordisk As | Insulin derivatives and compositions thereof |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5504188A (en) | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
| US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| AR002976A1 (es) | 1995-03-31 | 1998-05-27 | Lilly Co Eli | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
| US5902603A (en) | 1995-09-14 | 1999-05-11 | Cygnus, Inc. | Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use |
| TW520293B (en) | 1995-11-22 | 2003-02-11 | Univ Johns Hopkins Med | Delivery system to enhance cellular uptake of biomolecules |
| US5723589A (en) | 1995-12-21 | 1998-03-03 | Icn Pharmaceuticals | Carbohydrate conjugated bio-active compounds |
| US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| WO1998032867A1 (en) | 1997-01-24 | 1998-07-30 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| AR012894A1 (es) | 1997-06-13 | 2000-11-22 | Lilly Co Eli | Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma. |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| HUP0004169A3 (en) | 1997-10-24 | 2001-06-28 | Lilly Co Eli | Insoluble insulin compositions and process for production thereof |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| DE69924232D1 (de) | 1998-01-09 | 2005-04-21 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
| EP1071703B1 (en) | 1998-04-15 | 2005-07-20 | Novo Nordisk A/S | NOVEL PROCESS FOR THE SEPARATION OF PROTEINS USING A Ca++ CONTAINING ELUANT |
| US6300319B1 (en) * | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| US6844166B1 (en) | 1998-09-11 | 2005-01-18 | Sensor Technologies Inc. | Recombinant reduced valency carbohydrate binding ligands |
| US6323311B1 (en) | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
| US6777207B2 (en) | 1999-12-29 | 2004-08-17 | Novo Nordisk A/S | Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast |
| US6521738B2 (en) | 1999-12-29 | 2003-02-18 | Novo Nordisk A/S | Method for making insulin precursors and insulin precursor analogs |
| AU2001263775A1 (en) * | 2000-06-02 | 2001-12-11 | Novo-Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
| US7316999B2 (en) | 2000-06-02 | 2008-01-08 | Novo Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
| US6650951B1 (en) | 2000-06-19 | 2003-11-18 | International Business Machines Corporation | Method and insulin pump for providing a forgotten bolus warning |
| WO2002006789A2 (en) | 2000-07-13 | 2002-01-24 | The Ohio State University Research Foundation | Multimeric biopolymers as structural elements, sensors and actuators in microsystems |
| US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| WO2003047462A1 (en) | 2001-03-12 | 2003-06-12 | Clemson University | Polysaccharide-based polmerizable hydrogels |
| US7105314B2 (en) | 2001-04-02 | 2006-09-12 | Novo Nordisk A/S | Method for making human insulin precursors |
| EP2292273A3 (en) * | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| CA2478543A1 (en) | 2001-10-26 | 2003-04-26 | The Uab Research Foundation | Multidrug multiligand conjugates for targeted drug delivery |
| US6736796B2 (en) | 2001-11-26 | 2004-05-18 | Nili-Med Ltd. | Fluid drug delivery device |
| US7473680B2 (en) * | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
| EP1453860A2 (en) * | 2001-12-02 | 2004-09-08 | Novo Nordisk A/S | Novel glucose-dependant insulins |
| US7317000B2 (en) | 2001-12-02 | 2008-01-08 | Novo Nordisk A/S | Glucose-dependent insulins |
| WO2003048915A1 (en) | 2001-12-07 | 2003-06-12 | Ntt Docomo, Inc. | Mobile communication terminal, method for controlling execution state of application program, application program, and recording medium wherein application program has been recorded |
| US6744350B2 (en) | 2002-02-28 | 2004-06-01 | Smiths Medical Md, Inc. | Insulin pump having missed meal bolus alarm |
| US6852104B2 (en) | 2002-02-28 | 2005-02-08 | Smiths Medical Md, Inc. | Programmable insulin pump |
| DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
| WO2003094956A1 (en) | 2002-05-07 | 2003-11-20 | Novo Nordisk A/S | Soluble formulations comprising monomeric insulin and acylated insulin |
| US20080221020A1 (en) * | 2002-07-19 | 2008-09-11 | The Regents Of The University Of California | Dendrimers as Molecular Translocators |
| US7993108B2 (en) | 2002-10-09 | 2011-08-09 | Abbott Diabetes Care Inc. | Variable volume, shape memory actuated insulin dispensing pump |
| EP1575587A1 (en) * | 2002-10-29 | 2005-09-21 | Ranbaxy Laboratories, Ltd. | Iminosugar derivatives as glucosidase inhibitors |
| CA2509382A1 (en) * | 2002-12-17 | 2004-07-08 | Todd C. Zion | Stimuli-responsive systems for controlled drug delivery |
| AU2003294912B2 (en) | 2002-12-20 | 2009-06-04 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
| WO2004101619A1 (ja) * | 2003-05-15 | 2004-11-25 | Shionogi Co., Ltd. | 機能的糖ペプチドの合理的設計および合成 |
| EP1687428A1 (en) | 2003-11-14 | 2006-08-09 | Novo Nordisk A/S | Processes for making acylated insulin |
| WO2006088473A2 (en) | 2004-04-23 | 2006-08-24 | Panduranga Rao Koritala | Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents |
| WO2006008238A1 (en) | 2004-07-16 | 2006-01-26 | Novo Nordisk A/S | Method for selective acylation |
| CN101027318B (zh) | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
| WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
| US20070207498A1 (en) | 2005-02-24 | 2007-09-06 | Lifescan, Inc. | Design and construction of dimeric concanavalin a mutants |
| US20060247154A1 (en) | 2005-02-24 | 2006-11-02 | Lifescan, Inc. | Concanavalin a, methods of expressing, purifying and characterizing concanavalina, and sensors including the same |
| WO2006102762A1 (en) | 2005-04-01 | 2006-10-05 | Mcmaster University | Glucose responsive microgels |
| BRPI0616630B8 (pt) | 2005-09-30 | 2021-05-25 | Miikana Therapeutics Inc | compostos de pirazol substituídos |
| US20090111769A1 (en) | 2005-10-10 | 2009-04-30 | De Kort Martin | Antithrombotic Compound |
| US7517856B2 (en) | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
| WO2007047997A2 (en) | 2005-10-19 | 2007-04-26 | Smartcells, Inc. | Methods for reducing the mitogenicity of lectin compositions |
| JP5202338B2 (ja) | 2006-02-27 | 2013-06-05 | ノボ・ノルデイスク・エー/エス | 新規インシュリン誘導体 |
| US20100189643A1 (en) | 2006-07-24 | 2010-07-29 | Duke University | Drug delivery with stimulus responsive biopolymers |
| CN103169984B (zh) | 2006-07-25 | 2016-08-03 | 利普生技术有限公司 | N末端聚唾液酸化 |
| FR2904315B1 (fr) | 2006-07-26 | 2012-12-14 | Centre Nat Rech Scient | Composes pyridaziniques et pyrroliques, procedes d'obtention et applications |
| US20080172028A1 (en) | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having selectable insulin absorption models |
| US7515060B2 (en) | 2006-10-17 | 2009-04-07 | Smiths Medical Md, Inc. | Insulin pump for the visually impaired |
| CN101273961A (zh) | 2007-03-30 | 2008-10-01 | 中国人民解放军总医院 | 葡萄糖敏感水凝胶 |
| US20090053167A1 (en) | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
| US20090005726A1 (en) | 2007-06-27 | 2009-01-01 | Steven Paul Jones | Insulin Pump Having Expected Bolus Interval and an Early Bolus Interval |
| WO2009033588A2 (en) | 2007-09-11 | 2009-03-19 | F. Hoffmann-La-Roche Ag | Self-controlled insulin delivery system |
| WO2009059450A1 (en) | 2007-11-05 | 2009-05-14 | Shanghai Jiaotong University | Peptide ligand directed drug delivery |
| GB2446247B (en) | 2007-11-27 | 2008-12-17 | Robert Joseph Wagener | Homeostatic insulin pump |
| CN102037004A (zh) | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
| US20090177154A1 (en) | 2008-01-08 | 2009-07-09 | Michael Blomquist | Insulin pump with convenience features |
| US20090177142A1 (en) | 2008-01-09 | 2009-07-09 | Smiths Medical Md, Inc | Insulin pump with add-on modules |
| RU2381238C2 (ru) | 2008-01-31 | 2010-02-10 | Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (статус государственного учреждения) | Способ получения глюкозочувствительных полимерных гидрогелей |
| JP5781308B2 (ja) | 2008-02-19 | 2015-09-16 | バイオコン・リミテッドBiocon Limited | 異種タンパク質を得る方法およびインスリン類似体 |
| DK2141620T3 (en) | 2008-07-01 | 2019-02-18 | Hoffmann La Roche | Insulin pump and method for controlling one of the insulin pump's user interface |
| WO2010088276A2 (en) * | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Polynucleotide aptamer-based cross -linked materials and uses thereof |
| JP2012516338A (ja) * | 2009-01-28 | 2012-07-19 | スマートセルズ・インコーポレイテツド | 結合部位が修飾されたレクチンおよびその使用 |
| RU2011135730A (ru) * | 2009-01-28 | 2013-03-10 | Смартселлз, Инк. | Кристаллические инсулин-коньюгаты |
| JP2012516339A (ja) * | 2009-01-28 | 2012-07-19 | スマートセルズ・インコーポレイテツド | 外因的刺激型制御放出物質体およびその使用 |
| WO2010088286A1 (en) * | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
| WO2010088294A1 (en) * | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Conjugate based systems for controlled drug delivery |
| WO2010107520A1 (en) * | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| JP2012520879A (ja) * | 2009-03-20 | 2012-09-10 | スマートセルズ・インコーポレイテツド | 末端官能基化コンジュゲートおよびその用途 |
| US9095623B2 (en) * | 2009-03-20 | 2015-08-04 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
| EP2448962B1 (en) | 2009-06-30 | 2016-10-19 | Novo Nordisk A/S | Insulin derivatives |
| AU2011282983A1 (en) * | 2010-07-28 | 2013-02-21 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| WO2012015691A2 (en) * | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinant lectins, binding-site modified lectins and uses thereof |
| JP2013535467A (ja) * | 2010-07-28 | 2013-09-12 | スマートセルズ・インコーポレイテツド | 組換えにより発現されたインスリンポリペプチドおよびその使用 |
| US9884125B2 (en) * | 2013-10-04 | 2018-02-06 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
| EP3280450A4 (en) * | 2015-04-08 | 2018-12-12 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
| US9899205B2 (en) * | 2016-05-25 | 2018-02-20 | Kla-Tencor Corporation | System and method for inhibiting VUV radiative emission of a laser-sustained plasma source |
-
2010
- 2010-01-27 WO PCT/US2010/022268 patent/WO2010088294A1/en not_active Ceased
- 2010-01-27 NZ NZ594248A patent/NZ594248A/en not_active IP Right Cessation
- 2010-01-27 JP JP2011548259A patent/JP5508438B2/ja not_active Expired - Fee Related
- 2010-01-27 EA EA201170986A patent/EA027757B1/ru not_active IP Right Cessation
- 2010-01-27 BR BRPI1007457-0A patent/BRPI1007457A2/pt not_active IP Right Cessation
- 2010-01-27 PE PE2011001411A patent/PE20120583A1/es not_active Application Discontinuation
- 2010-01-27 CN CN201080015055XA patent/CN102365025A/zh active Pending
- 2010-01-27 SG SG2011053311A patent/SG173112A1/en unknown
- 2010-01-27 CA CA2932926A patent/CA2932926C/en not_active Expired - Fee Related
- 2010-01-27 EP EP10736354.1A patent/EP2391218B1/en active Active
- 2010-01-27 MX MX2011007929A patent/MX2011007929A/es active IP Right Grant
- 2010-01-27 KR KR1020117017641A patent/KR20110104081A/ko not_active Ceased
- 2010-01-27 SG SG2014006597A patent/SG2014006597A/en unknown
- 2010-01-27 ES ES10736354T patent/ES2791683T3/es active Active
- 2010-01-27 CN CN201610103747.9A patent/CN105753965A/zh active Pending
- 2010-01-27 SG SG2013065412A patent/SG193837A1/en unknown
- 2010-01-27 MA MA34121A patent/MA33064B1/fr unknown
- 2010-01-27 CA CA2750262A patent/CA2750262C/en not_active Expired - Fee Related
- 2010-01-27 US US13/145,532 patent/US9050370B2/en active Active
- 2010-01-27 KR KR1020147001684A patent/KR101635689B1/ko not_active Expired - Fee Related
-
2011
- 2011-07-14 IL IL214099A patent/IL214099A0/en unknown
- 2011-07-15 TN TN2011000354A patent/TN2011000354A1/fr unknown
- 2011-07-27 NI NI201100150A patent/NI201100150A/es unknown
- 2011-07-27 GT GT201100208A patent/GT201100208A/es unknown
- 2011-07-28 EC EC2011011240A patent/ECSP11011240A/es unknown
- 2011-07-28 CR CR20110408A patent/CR20110408A/es unknown
- 2011-07-28 DO DO2011000244A patent/DOP2011000244A/es unknown
- 2011-07-28 CO CO11095147A patent/CO6400173A2/es not_active Application Discontinuation
-
2014
- 2014-03-20 JP JP2014057357A patent/JP5834103B2/ja not_active Expired - Fee Related
- 2014-05-30 US US14/291,021 patent/US9265838B2/en active Active
-
2015
- 2015-05-27 AU AU2015202871A patent/AU2015202871B2/en not_active Ceased
- 2015-05-27 AU AU2015202872A patent/AU2015202872B2/en not_active Ceased
- 2015-06-04 US US14/731,016 patent/US9579391B2/en active Active
- 2015-11-02 JP JP2015215913A patent/JP6040301B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-10 US US15/040,004 patent/US20160193351A1/en not_active Abandoned
-
2017
- 2017-08-18 US US15/680,262 patent/US10398781B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Revisiting carbazole: origin, impurity, and properties | |
| Voznyy et al. | Origins of stokes shift in PbS nanocrystals | |
| Jeitschko | The crystal structure of Fe2AlB2 | |
| He et al. | Perovskite spin light-emitting diodes with simultaneously high electroluminescence dissymmetry and high external quantum efficiency | |
| MX346145B (es) | Composición de sistema de suministro de arnsi in vivo basado en péptidos. | |
| ECSP11011241A (es) | Sistemas basados en conjugados para entrega farmacológica controlada | |
| DE602007009489D1 (de) | Stabilisierte pharmazeutische zusammensetzung | |
| AR072199A1 (es) | Derivados de fenilimidazol como inhibidores de la enzima pde10a | |
| DOP2011000244A (es) | Sistemas basados en conjugados para entrega farmacologica controlada | |
| Li et al. | Effects of polymorphic DNA on the fluorescent properties of silver nanoclusters | |
| JP6299224B2 (ja) | 有機エレクトロルミネッセンス表示装置 | |
| BR112013011149A2 (pt) | adutos poliacetal, métodos de fabricação e seus usos. | |
| Wu et al. | Controlling Morphological Dimensions of Organic Charge‐Transfer Cocrystal by Manipulating the Growth Kinetics for Optical Waveguide Applications | |
| PE20140860A1 (es) | Compuestos de pirazol como antagonistas de crth2 | |
| AR052090A1 (es) | Procedimiento para manufacturar un sacarido cristalino eutectico polvo de hidrolizado de almidon hidrogenado y compuesto que contiene dicho sacarido cristalino eutectico | |
| CN104649923B (zh) | 1-氨基-12-羟基-3,4,9,10-苝四羧酸正丁酯及其合成方法 | |
| BR112014013906A8 (pt) | ésteres de fosfato aromáticos como componentes de formulação agroquímica | |
| MD4484B1 (ro) | Forma cristalină VIII a agomelatinei, procedeu de preparare, utilizarea acesteia şi compoziţie farmaceutică care o conţine | |
| PE20061014A1 (es) | Clorhidrato de lercanidipina amorfo | |
| PE20131327A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen | |
| Li et al. | Sucralose, an activator of the glucose-sensing receptor, increases ATP by calcium-dependent and-independent mechanisms | |
| JP5858274B2 (ja) | 結晶化促進方法、結晶化解析方法、結晶の製造方法、結晶化装置の制御プログラム、記録媒体、及び結晶化装置 | |
| Fan et al. | Facile Uniaxial Electrospinning Strategy To Embed CsPbBr3 Nanocrystals with Enhanced Water/Thermal Stabilities for Reversible Fluorescence Switches | |
| CN104194770A (zh) | 一种具有紫色发光性能的荧光材料及其制备方法 | |
| AR055671A1 (es) | Proceso de fabricacion de derivados de quinazolina |